

共享成果，助力科研

国际期刊《肿瘤学家》杂志旗下Clinical Trial Results(CTR)平台，助您快速发布临床研究结果的第一选择！

临床研究结果和数据的透明化趋势越发明显，全球范围内政府机构、业界及学术界共同努力加以推动。CTR将其视为临床试验质量管理规范的一部分，致力于推动所有临床研究结果的共享，加速临床治疗的进步，加快试验结果向临床应用和学习的转化。

CTR采用开放存取(Open Access)格式，确保对不同类型的数据结果都能够快速进行审核发表。


CTR平台由两部分组成：

- 1) “作者概要” - 将以印刷版形式发表
“作者概要”能让读者快速获取研究目的和设计，由格式化的“摘要”（200字以内）和简单“讨论”两部分组成。
“讨论”可以有两种：一种是350字加两个图表，或是450字加一个图表。
- 2) “附加数据”，包含所有的支持文档以及一份延展的“讨论”，将在线发表。
“作者概要”和完整的CTR共享同样的标题，并在Pubmed中以相同的DOI(Document Object Identifier)进行引用。

共同开发者&共同主编



Susan E. Bates, M.D.
Director
Translational Cancer Medicine
Columbia University Medical Center
New York, New York



Antonio Tito Fojo, M.D., Ph.D.
Director
Neuroendocrine Cancer
Columbia University Medical Center
New York, New York

独特优势

- 全球开放存取
- 独有的标准化格式
- 独有在线统计学工具支持图表自动生成
- 快速审评，发表快
- 不收取版面费
- 明确的数据知识产权保护
- 广泛适用于I/II/III期临床研究
- Pubmed/MEDLINE收录



欢迎您的加入！
访问下面链接，即可快速发表
您的临床研究结果！

<http://CTRCollection.TheOncologist.com>



不需前期文字准备，一切均可在线完成！

1. 简单注册获取访问权限
2. 点击“Submit Your Clinical Trial”
3. 根据提示条目，逐条描述您的研究
4. 使用在线提供的统计学工具，生成瀑布图，Kaplan-Meier曲线以及不良事件图表
5. 正式递交前再次审核
6. 点击“Submit Result”，即进入编辑审稿环节

Adverse Events

Version: CTCAE v4.0

Number of Patients/Cycles: Number of Patients

Adverse Events At All Dose Levels, Cycle 1

Add Adverse Events

Select an Adverse Event

Respiratory, thoracic and mediastinal disorders

- Allergic rhinitis
- Pulmonary hypertension
- Laryngeal mucositis
- Tracheal mucositis
- Pharyngeal mucositis
- Pharyngeal fistula
- Pharyngeal stenosis

Name: N/C/N/A

Bone pain: 3

Cough: 9

Fatigue: 11

Adverse Events



Adverse Events At All Dose Levels, Cycle 1

Name	*N/C/N/A	1	2	3	4	5	All Grades
Bone pain	14.29%	23.81%	52.38%	9.52%	0.0%	0.0%	85.0%
Cough	42.86%	47.62%	9.52%	0.0%	0.0%	0.0%	57.0%
Fatigue	52.38%	14.29%	28.57%	4.76%	0.0%	0.0%	47.0%
Localized edema	57.14%	19.05%	23.81%	0.0%	0.0%	0.0%	42.0%
Anorexia	61.9%	19.05%	14.29%	4.76%	0.0%	0.0%	38.0%
Abdominal pain	66.67%	19.05%	14.29%	0.0%	0.0%	0.0%	33.0%
Weight loss	66.67%	14.29%	19.05%	0.0%	0.0%	0.0%	33.0%
Hyperglycemia	71.43%	0.0%	19.05%	9.52%	0.0%	0.0%	28.0%
Cholesterol high	71.43%	19.05%	9.52%	0.0%	0.0%	0.0%	28.0%
Constipation	76.19%	4.76%	19.05%	0.0%	0.0%	0.0%	23.0%
Hypokalemia	80.95%	14.29%	0.0%	4.76%	0.0%	0.0%	19.0%
Nausea	85.71%	14.29%	0.0%	0.0%	0.0%	0.0%	14.0%

*No Change from Baseline/No Adverse Event

Adverse Events Legend

Summary of adverse events of any grade during treatment/therapy reported in >10% of patients or of grade 3 or higher if encountered in >5% of patients.



Submit Result

PUBLISHED CLINICAL TRIAL RESULTS

81+ trials published

已有15个瘤种的数十个化疗及靶向药物相关的临床研究结果通过CTR平台进行了发表！

From phase I feasibility studies of novel agents to larger-scale phase II trials studying efficacy and tolerability of combination therapies, CTR offers helpful insights into a variety of therapeutic approaches, some successful, others not, but all of which can inform future research.

近期发表的研究：

- Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer
- Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy
- A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer
- A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone
- A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapse Small-Cell Lung Cancer
- A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors

CTR平台发表的所有临床研究结果都被Medline/PUBMED所收录！